FDA Panel Votes To Clear GlaxoSmithKline Rotavirus Vaccine For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK’s Rotarix gets nod from FDA’s Vaccines and Related Biological Products Advisory Committee.
You may also be interested in...
GSK’s Rotarix U.S. Launch Scheduled For Second Half
FDA approves the two-dose rotavirus vaccine, which will compete against Merck’s three-dose vaccine, RotaTeq.
GSK’s Rotarix U.S. Launch Scheduled For Second Half
FDA approves the two-dose rotavirus vaccine, which will compete against Merck’s three-dose vaccine, RotaTeq.
FDA Panel Will Review Rotarix Pneumonia-Related Events
Agency analysis of GlaxoSmithKline rotavirus vaccine showed more pneumonia-related deaths and convulsions in clinical studies.